Cyclosporine treatment of high dose and long duration reduces the severity of graft coronary artery disease in rodent cardiac allografts
Authors:
- David T. CookeDCDavid T. Cooke
- Jasper M. MartensJMJasper M. Martens
- Murray H. KownMKMurray H. Kown
- Seiichiro MurataSMSeiichiro Murata
- Shannon H. PetersonSPShannon H. Peterson
- E.GRant HoytEHE.GRant Hoyt
- Robert C. RobbinsRRRobert C. Robbins
- 1 April 2005
- journal article
- research article
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 24 (4) , 439-445
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The major histocompatibility complex of the rat (Rattus norvegicus)Immunogenetics, 2001
- The registry of the international society for heart and lung transplantation: eighteenth official report—2001The Journal of Heart and Lung Transplantation, 2001
- Cardiac allograft vasculopathyCurrent Opinion in Cardiology, 2000
- Active cell migration in retransplanted rat cardiac allografts during the course of chronic rejectionThe Journal of Heart and Lung Transplantation, 2000
- Neoral use in the cardiac transplant recipientTransplantation Proceedings, 2000
- Rapamycin Reverses Chronic Graft Vascular Disease in a Novel Cardiac Allograft ModelCirculation, 1999
- The risk of coronary artery disease after heart transplantation is increased in patients receiving low‐dose cyclosporine, regardless of blood cyclosporine levelsClinical Cardiology, 1997
- Pathogenesis and Treatment Perspectives of Chronic Graft Rejection (CVR)Immunological Reviews, 1993
- EFFECTS OF CYCLOSPORINE ON SYSTEMIC MHC EXPRESSIONTransplantation, 1988
- Massive induction of donor-type class I and class II major histocompatibility complex antigens in rejecting cardiac allografts in the rat.Journal of Experimental Medicine, 1985